Literature DB >> 11685701

Novel capsaicin (VR1) and purinergic (P2X3) receptors in Hirschsprung's intestine.

P Facer1, C H Knowles, P K Tam, A P Ford, N Dyer, P A Baecker, P Anand.   

Abstract

BACKGROUND/
PURPOSE: Studies of Hirschsprung's disease (HSCR) have shown that hypertrophic nerves in aganglionic bowel are mainly of extrinsic origin and may contain sensory elements. Recent advances have shown a specific capsaicin receptor VR1 (vanilloid receptor-1), and an ATP-gated ion channel P2X(3), which are expressed by sensory neurons.
METHODS: This study investigated, for the first time, the distribution of VR1- and P2X(3)-immunoreactivity in normal adult, infant, and HSCR large intestine, using specific antibodies for immunohistochemistry.
RESULTS: VR1-immunoreactive fibers and nerve fascicles, but not somata, were detected in all regions of the bowel in controls with few weakly immunostained fibers in the mucosa/lamina propria. Hypertrophic nerve bundles in hypoganglionic and aganglionic bowel showed intense VR1-immunoreactivity, whereas normoganglionic regions of HSCR were similar to controls. P2X(3)-immunoreactive neuronal cell bodies, in some instances with long axonal processes, were detected in the myenteric and submucous plexuses in control infant, adult, and ganglionic HSCR samples. Aganglionic samples showed weak P2X(3)-immunoreactivity in hypertrophic nerve fasciculi in the submucous and myenteric plexuses.
CONCLUSIONS: The presence of VR1- and P2X(3)-immunoreactivities in aganglionic HSCR bowel indicates that sensory nerves may form a significant proportion of its hypertrophic innervation. The functional significance of P2X(3) and VR1 receptors in enteric nerves deserves further investigation. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685701     DOI: 10.1053/jpsu.2001.27959

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  15 in total

Review 1.  Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system.

Authors:  Peter Holzer
Journal:  Pharmacol Ther       Date:  2011-03-21       Impact factor: 12.310

2.  Endocannabinoid overactivity and intestinal inflammation.

Authors:  V Di Marzo; A A Izzo
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  Distribution of P2X(3) receptor immunoreactivity in myenteric ganglia of the mouse esophagus.

Authors:  Christine Kestler; Winfried L Neuhuber; Marion Raab
Journal:  Histochem Cell Biol       Date:  2008-09-20       Impact factor: 4.304

4.  Are rice and spicy diet good for functional gastrointestinal disorders?

Authors:  Sutep Gonlachanvit
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

Review 5.  Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function.

Authors:  Pierangelo Geppetti; Marcello Trevisani
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

Review 6.  Enteric P2X receptors as potential targets for drug treatment of the irritable bowel syndrome.

Authors:  James J Galligan
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

7.  Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat.

Authors:  S Hong; J Fan; E S Kemmerer; S Evans; Y Li; J W Wiley
Journal:  Gut       Date:  2008-10-20       Impact factor: 23.059

8.  Purinergic receptors and gastrointestinal secretomotor function.

Authors:  Fievos Leontiou Christofi
Journal:  Purinergic Signal       Date:  2008-07-05       Impact factor: 3.765

9.  Shugan-decoction relieves visceral hyperalgesia and reduces TRPV1 and SP colon expression.

Authors:  Jing-Juan Shang; Jian-Ye Yuan; Hui Xu; Rong-Zhu Tang; Yue-Bin Dong; Jian-Qun Xie
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 10.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.